Aziyo Biologics’ $50 Million Initial Public Offering

Davis Polk advised the representatives of the several underwriters in the offering.

Aziyo Biologics, Inc. completed the $50 million initial public offering of common stock. The common stock is listed on the Nasdaq Global Market under the symbol “AZYO.”

Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices.

The Davis Polk corporate team advising Piper Sandler & Co. and Cowen and Company, LLC, as representatives of the several underwriters, included partner Alan F. Denenberg (Picture) and associates Ali DeGolia and Lawrence Edward Traylor Jr. The tax team included partner Mario J. Verdolini and associate Shay Moyal. Partner David R. Bauer and associates Jesse L. Hallock and Brette L. Trost provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Sijia Cai provided 1940 Act advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Sijia Cai – Davis Polk & Wardwell; Ali DeGolia – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Shay Moyal – Davis Polk & Wardwell; Lawrence Edward Traylor Jr. – Davis Polk & Wardwell; Brette Trost – Davis Polk & Wardwell; Mario Verdolini – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Cowen and Company; Piper Sandler;

Author: Ambrogio Visconti